GEN Exclusives

More »

GEN News Highlights

More »
Sep 28, 2006

Inyx to Acquire Pharmapac in Deal Valued at Over $17M

  • Inyx Pharma executed a definitive agreement to acquire Pharmapac, a contract pharmaceutical production and packaging provider in the U.K. The acquisition is expected to be completed by November 14, 2006. The purchase price is approximately $17 million in cash at closing plus $2.9 million in cash if certain milestones are met in 2007 and 2008.

    “This is another strategic acquisition for Inyx. Pharmapac is highly profitable and a strong cash generator and it has a network of complementary distribution and packaging customers,” says Jack Kachkar, M.D., chairman and CEO of Inyx.

    “The addition of Pharmapac’s dedicated packaging facility will enable Inyx to provide a dynamic secondary-packaging resource for a wide range of dosage forms needed to serve high-demand respiratory, allergy, dermatology, and topical product sectors. Pharmapac increases Inyx’ capabilities to provide innovative packaging designs for new formulations and drug delivery systems being utilized today by our clients, as well as by Inyx.”


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

The Triple Package and Success

One theory for explaining “success," put forward by Amy Chua Jed Rubenfeld, posits cultural traits such as a superiority complex, personal insecurity and impulse control. Union College professors Joshua Hart and Christopher Chabris counter that intelligence, conscientiousness, and economic advantage are the most likely elements of success, regardless of ethnicity. Do you think that Hart-Chabris make a better argument for achieving success than the Chua-Rubenfeld theory?

More »